Calcineurin inhibitors: 40 years later, can’t live without
The DOI matches its Crossref record; 87 of the 90 references it cites were found in a registry or an index.
Abstract
Calcineurin inhibitors (CNIs) revolutionized the field of organ transplantation and remain the standard of care 40 years after the discovery of cyclosporine. The early impressive results of cyclosporine in kidney transplant recipients led to its subsequent use in other organ transplant recipients and for treatment of a variety of autoimmune diseases as well. In this review, we examine the discovery of CNIs, their mechanism of action, preclinical and clinical studies with CNIs, and the usage of CNIs in nontransplant recipients. We review the mechanisms of renal toxicity associated with CNIs and the recent efforts to avoid or reduce usage of these drugs. Although minimization strategies are possible, safe, and of potential long-term benefit, complete avoidance of CNIs has proven to be more challenging than initially thought.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Calcineurin inhibitors, including ciclosporin and tacrolimus, inhibit T cell proliferation and activation through targeting IL-2 (58).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [58]
In the citing paper
“Ciclosporin and tacrolimus are immunosuppressants that inhibit calcineurin, a key signaling phosphatase, by binding to their respective immunophilins - cyclophilin and FKBP12 (76).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [76]
In the citing paper
“A major downstream effect is suppression of interleukin (IL)-2 transcription, thereby inhibiting T cells differentiation, survival, and subsequent antibody production and CTL activities via effector TH cells.”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [76]
Citations
Cites
Regulatory T Cells and Immune Tolerance
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,325 · cited 2×
“Regulatory T cells have been shown to be essential for immune tolerance induction in transplantation (16).”
BackgroundTRANSCRIPTION FACTORS OF THE NFAT FAMILY:Regulation and Function
Rao, A., Luo, C., & Hogan, P. G. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.707 · Cited by 2,603 · cited 1×
“scriptional activation of genes encoding cytokines, including IL-2 and IL-4, and CD40 ligand (12).”
BackgroundThe Natural History of Chronic Allograft Nephropathy
Nankivell, B. J., Borrows, R. J., Fung, C. L.-S., O'Connell, P. J., Allen, R. D. M., & Chapman, J. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020009 · Cited by 1,949
Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation
Ekberg, H., Tedesco-Silva, H., Demirbas, A., Vítko, Š., Nashan, B., Gürkan, A., Margreiter, R., Hugo, C., Grinyó, J. M., Frei, U., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067411 · Cited by 1,810
Creighton, T. E. (1992) · Cited by 1,583
Biological effects of cyclosporin A: A new antilymphocytic agent
Borel, J. F., Feurer, C., Gubler, H. U., & Stähelin, H. (1976) · Agents and Actions · doi:10.1007/bf01973261 · Cited by 1,509 · cited 1×
“Many mechanisms were suggested, including an imbalance between vasoconstrictive and vasodilatory mediators (46), an activation of the renin-angiotensin-aldosterone system (47), an increase in the release of endothelin (5), an increase in free radicals (48), and a sympathetic nerve activation in the native kidneys thro…”
BackgroundPirsch, J. D., Miller, J., Deierhoi, M. H., Vincenti, F., & Filo, R. S. (1997) · Transplantation · doi:10.1097/00007890-199704150-00013 · Cited by 1,122
Calne, R. Y., Rolles, K., Thiru, S., Mcmaster, P., Craddock, G. N., Aziz, S., White, D. J. G., Evans, D. B., Dunn, D. C., Henderson, R. G., et al. (1979) · The Lancet · doi:10.1016/s0140-6736(79)92440-1 · Cited by 1,083
CYCLOSPORIN A IN PATIENTS RECEIVING RENAL ALLOGRAFTS FROM CADAVER DONORS
Calne, R. Y., Thiru, S., Mcmaster, P., Craddock, G. N., White, D. J. G., Evans, D. B., Dunn, D. C., Pentlow, B. D., & Rolles, K. (1978) · The Lancet · doi:10.1016/s0140-6736(78)91970-0 · Cited by 1,002 · cited 1×
“The nephrotoxicity of cyclosporine, reported by Calne and colleagues in the early human studies, remains a major concern for the medical community today (21).”
BackgroundVincenti, F., Charpentier, B., Vanrenterghem, Y., Rostaing, L., Bresnahan, B., Darji, P., Massari, P., Mondragon‐Ramirez, G. A., Agarwal, M., Di Russo, G., et al. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.03005.x · Cited by 957 · cited 2×
“The cardiovascular and metabolic profiles were better in belatacept groups compared with patients receiving cyclosporine (70).”
Background
Research works printed but not linked: 1
- Klee, 1988, Calcineurin, Adv. Enzymol. Relat. Areas Mol. Biol., 61, 149
Cited by
Loomba, R., & Liang, T. J. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.02.009 · Cited by 594
“Immunophilin inhibitors, such as cyclosporine, suppress T-lymphocyte functions by binding to immunophilins and inhibiting interleukin production.(59) Thus, it is not surprising that these general immunosuppressive effects lead to broad immune dysfunctions and potential HBV reactivation.”
BackgroundRole of Mitochondrial Calcium and the Permeability Transition Pore in Regulating Cell Death
Bauer, T. M., & Murphy, E. (2020) · Circulation Research · doi:10.1161/circresaha.119.316306 · Cited by 439
Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease
Decourt, B., Lahiri, D. K., & Sabbagh, M. N. (2017) · Current Alzheimer Research · doi:10.2174/1567205013666160930110551 · Cited by 371
Store-Operated Ca2+ Entry Controls Clonal Expansion of T Cells through Metabolic Reprogramming
Vaeth, M., Maus, M., Klein-Hessling, S., Freinkman, E., Yang, J., Eckstein, M., Cameron, S., Turvey, S. E., Serfling, E., Berberich-Siebelt, F., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.09.003 · Cited by 276
“12 Immunity 47, 1–16, October 17, 2017 long use of CsA and tacrolimus, a satisfying understanding of the molecular mechanism by which calcineurin inhibition regulates T cell proliferation is missing (Azzi et al., 2013).”
InfluentialStrzelec, M., Detka, J., Mieszczak, P., Sobocińska, M. K., & Majka, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1127704 · Cited by 233
Revisiting the Concept of Targeting NFAT to Control T Cell Immunity and Autoimmune Diseases
Lee, J.-U., Kim, L.-K., & Choi, J.-M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02747 · Cited by 190
“Considering the important role of NFAT signaling in T cell function, NFAT has long been considered as an attractive target for therapeutic approaches to control autoimmune responses and graft rejection (Table 2) (30, 31, 163, 164).”
BackgroundLiver Regeneration after Hepatectomy and Partial Liver Transplantation
Yagi, S., Hirata, M., Miyachi, Y., & Uemoto, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218414 · Cited by 192
Park, H.-S., Lee, S. C., Cardenas, M. E., & Heitman, J. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.08.004 · Cited by 168
“A variety of studies demonstrated that calcineurin inhibitors show synergistic effects with other anti-fungal agents (Azzi et al., 2013).”
BackgroundT lymphocytes and fractalkine contribute to myocardial ischemia/reperfusion injury in patients
Boag, S. E., Das, R., Shmeleva, E. V., Bagnall, A., Egred, M., Howard, N., Bennaceur, K., Zaman, A., Keavney, B., & Spyridopoulos, I. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80055 · Cited by 154
Calcium signaling and endoplasmic reticulum stress
Groenendyk, J., Agellon, L. B., & Michalak, M. (2021) · International review of cytology · doi:10.1016/bs.ircmb.2021.03.003 · Cited by 179
Physiological Functions of CRAC Channels
Emrich, S. M., Yoast, R. E., & Trebak, M. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-052521-013426 · Cited by 140
NFAT as cancer target: Mission possible?
Qin, J., Nag, S. A., Wang, W., Zhou, J., Zhang, W., Wang, H., & Zhang, R. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.07.009 · Cited by 143
Juvvadi, P. R., Fox, D., Bobay, B. G., Hoy, M. J., Gobeil, S. M. C., Venters, R. A., Chang, Z., Lin, J. J., Averette, A. F., Cole, D. C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12199-1 · Cited by 116
Budde, K., Prashar, R., Haller, H. G., Rial, M. C., Kamar, N., Agarwal, A., de Fijter, J. W., Rostaing, L. P. E., Berger, S. P., Djamali, A., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021050628 · Cited by 105
“These results were consistent regardless of whether the eGFR changes were assessed from baseline or from month 3, suggesting that the observed improvement in eGFR following conversion from CNI to belatacept may not, by itself, be fully explained by early improvement in renal cortical blood flow following CNI discontin…”
BackgroundResultTargeted Delivery of Immunomodulators to Lymph Nodes
Azzi, J. R., Yin, Q., Uehara, M., Ohori, S., Tang, L., Cai, K., Ichimura, T., McGrath, M. M., Maarouf, O. H., Kefaloyianni, E., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.007 · Cited by 101
“NFAT increases the activity of IL-2 and other cytokine-encoding genes (Azzi et al., 2013; Kolata, 1983; Zhang et al., 1996).”
Self-citationGangwal, A., & Lavecchia, A. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104360 · Cited by 129
Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment
Peláez-Jaramillo, M. J., Cárdenas-Mojica, A. A., Gaete, P. V., & Mendivil, C. O. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0374-8 · Cited by 89
“Both cyclosporine and tacrolimus were developed by multidisciplinary research teams working at pharmaceutical companies and searching for immunosuppressants with a mild profile of cytotoxic adverse effects [39].”
BackgroundTang, Q., Leung, J., Peng, Y., Fueyo, A. S., Lozano, J. J., Lam, A., Lee, K., Greenland, J. R., Hellerstein, M. K., Fitch, M. D., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo2628 · Cited by 94
“We speculate that one contribution may be immunosuppression use in humans after liver transplantation (44).”
BackgroundPhosphorylation-Dependent Regulation of Mammalian Aquaporins
Nešverová, V., & Törnroth‐Horsefield, S. (2019) · Cells · doi:10.3390/cells8020082 · Cited by 94
“As such, this area of aquaporin regulation represents a vast knowledge gap, which should be addressed, in particular since protein phosphatases are attractive drug targets, an example being the calcineurin inhibitors, which are already on the market and used as immuno-suppressives [63].”
BackgroundTacrolimus for the management of psoriasis: clinical utility and place in therapy
Malecic, N., & Young, H. S. (2016) · Psoriasis Targets and Therapy · doi:10.2147/ptt.s101233 · Cited by 82
“However, there appear to be safety advantages to treatment with tacrolimus in comparison to ciclosporin, based on both the clinical results in psoriasis and the experience in transplantation medicine.(45) A recently published study in children with glomerulonephri-”
Deng, X., Wang, Y., Jiang, L., Li, J., & Chen, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1023213 · Cited by 100
Advances in autoimmune myasthenia gravis management
Wang, S., Breskovska, I., Gandhy, S., Punga, A. R., Guptill, J. T., & Kaminski, H. J. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1491310 · Cited by 80
“Cyclosporine is a highly specific inhibitor of T-cell activation [131,138].”
BackgroundSystematic Discovery of Short Linear Motifs Decodes Calcineurin Phosphatase Signaling
Wigington, C. P., Roy, J., Damle, N. P., Yadav, V. K., Blikstad, C., Resch, E., Wong, C. J., Mackay, D. R., Wang, J., Krystkowiak, I., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.06.029 · Cited by 79
Immunosuppressive drugs modes of action
Meneghini, M., Bestard, O., & Grinyo, J. M. (2021) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2021.101757 · Cited by 99
A CELLULAR ATLAS OF CALCINEURIN SIGNALING
Ulengin-Talkish, I., & Cyert, M. S. (2022) · Biochimica et biophysica acta. Molecular cell research · doi:10.1016/j.bbamcr.2022.119366 · Cited by 61
Reformulating cyclosporine A (CsA): More than just a life cycle management strategy
Guada, M., Beloqui, A., Kumar, M. N. V. R., Préat, V., Dios-Viéitez, M. D. C., & Blanco‐Prieto, M. J. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.056 · Cited by 78
Artificial Intelligence: Present and Future Potential for Solid Organ Transplantation
Peloso, A., Moeckli, B., Delaune, V., Oldani, G., Andres, A., & Compagnon, P. (2022) · Transplant International · doi:10.3389/ti.2022.10640 · Cited by 67
“The discovery of cyclosporine was a cornerstone of modern transplantation (24) and constant re fi nement of immunosuppressive regimens drastically improved outcomes for transplant patients (25).”
Management of dyslipidemia in adult solid organ transplant recipients
Warden, B. A., & Duell, P. B. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.01.011 · Cited by 79
Managing Sjögren’s Syndrome and non-Sjögren Syndrome dry eye with anti-inflammatory therapy
de Paiva, C. S., & Coursey, T. G. (2014) · Clinical ophthalmology · doi:10.2147/opth.s35685 · Cited by 71
“CsA binds calcineurin, thereby inhibiting its action and preventing the transcription of IL-2, which leads to inhibition of T-cell activation.(153,154) CsA was first used in the late 1980s to treat dry eye disease in dogs that developed spontaneous KCS.”
Inflammation as a Risk of Developing Chronic Kidney Disease in Rheumatoid Arthritis
Kochi, M., Kohagura, K., Shiohira, Y., Iseki, K., & Ohya, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160225 · Cited by 71
“Calcineurin inhibitors, such as cyclosporine and tacrolimus, can induce declining GFR[23].”
BackgroundPossible alternative therapies for oral lichen planus cases refractory to steroid therapies
Yang, H., Wu, Y., Ma, H., Jiang, L., Zeng, X. Y., Dan, H., Zhou, Y. J., & Chen, Q. (2016) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2016.02.002 · Cited by 64
Identification of Novel Nuclear Factor of Activated T Cell (NFAT)-associated Proteins in T Cells
Gabriel, C. H., Gross, F., Karl, M., Stephanowitz, H., Hennig, A. F., Weber, M., Gryzik, S., Bachmann, I., Hecklau, K., Wienands, J., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.739326 · Cited by 62
“Hence, inhibition of NFAT activation by cyclosporine A or tacrolimus is highly immunosuppressive and is applied to prevent transplant rejection and to treat various autoimmune diseases (12, 13).”
BackgroundTremain, A. C., Wallace, R. P., Lorentz, K. M., Thornley, T. B., Antane, J. T., Raczy, M. M., Reda, J. W., Alpar, A. T., Slezak, A. J., Watkins, E. A., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01086-2 · Cited by 63
Managing allorejection in off-the-shelf CAR-engineered cell therapies
Li, Y.-R., Fang, Y., Niu, S., Chen, Y., Lyu, Z., & Yang, L. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.035 · Cited by 70
“102 The mTOR is a conserved serine/threonine protein kinase essential for regulating cellular metabolism, growth, proliferation, and survival. mTOR operates within two distinct complexes: mTORC1, which predominantly controls cell growth and metabolism, and mTORC2, which governs cell proliferation…”
Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies
Chu, W. S., & Ng, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658038 · Cited by 59
Now or never? The case for cell-based immunosuppression in kidney transplantation
Hutchinson, J. A., & Geissler, E. K. (2015) · Kidney International · doi:10.1038/ki.2015.50 · Cited by 59
A versatile toolkit for overcoming AAV immunity
Li, X., Wei, X., Lin, J., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991832 · Cited by 57
Autophagy: A new concept in autoimmunity regulation and a novel therapeutic option
Bonam, S. R., Wang, F., & Muller, S. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.08.009 · Cited by 57
Chiou, F. K., Beath, S. V., Wilkie, G. M., Vickers, M. A., Morland, B. J., & Gupte, G. L. (2018) · Pediatric Transplantation · doi:10.1111/petr.13133 · Cited by 53
Local delivery strategies to restore immune homeostasis in the context of inflammation
Bentley, E. R., & Little, S. R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113971 · Cited by 50
Interplay between calcium and endoplasmic reticulum stress
Groenendyk, J., & Michalak, M. (2023) · Cell Calcium · doi:10.1016/j.ceca.2023.102753 · Cited by 51
Jee, A. S., & Corte, T. J. (2019) · Drugs · doi:10.1007/s40265-019-01178-x · Cited by 51
Calcium-calcineurin signaling pathway in Candida albicans: A potential drug target
Li, W., Shrivastava, M., Lu, H., & Jiang, Y. (2021) · Microbiological Research · doi:10.1016/j.micres.2021.126786 · Cited by 47
A Friend or Foe: Calcineurin across the Gamut of Neurological Disorders
Saraf, J., Bhattacharya, P., Kalia, K., Borah, A., Sarmah, D., Kaur, H., Dave, K., & Yavagal, D. (2018) · ACS Central Science · doi:10.1021/acscentsci.8b00230 · Cited by 44
Does HLA matching matter in the modern era of renal transplantation?
Kim, J. J., Fuggle, S. V., & Marks, S. D. (2019) · Pediatric Nephrology · doi:10.1007/s00467-019-04393-6 · Cited by 47
Divard, G., Aubert, O., Debiais, C., Raynaud, M., Goutaudier, V., Sablik, M., Sayeg, C., Legendre, C. M., Obert, J., Anglicheau, D., et al. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000411 · Cited by 49
Intestinal HAdV Infection: Tissue Specificity, Persistence, and Implications for Antiviral Therapy
Kosulin, K. (2019) · Viruses · doi:10.3390/v11090804 · Cited by 49
Tregs in transplantation tolerance: role and therapeutic potential
Cassano, A., Chong, A. S., & Alegre, M. (2023) · Frontiers in Transplantation · doi:10.3389/frtra.2023.1217065 · Cited by 52
Otsuka, S., Mélis, N., Gaida, M. M., Dutta, D., Weigert, R., & Ashwell, J. D. (2021) · Journal of Clinical Investigation · doi:10.1172/jci147683 · Cited by 47
“The last group is composed of cyclosporin A (CsA) and FK506 (Tacrolimus), therapeutic mainstays that have been used for more than 30 years (5).”
BackgroundHER2 signaling regulates HER2 localization and membrane retention
Jeong, J., Kim, W., Kim, L. K., VanHouten, J. N., & Wysolmerski, J. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174849 · Cited by 45
Hepatitis B Virus Reactivation Associated With Therapeutic Interventions
Chang, Y. W., Jeong, S. W., & Jang, J. Y. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.770124 · Cited by 47
“Calcineurin Inhibitors Calcineurin inhibitors such as cyclosporine or tacrolimus suppress T cell function by inhibiting calcineurin required for signal transduction of T cell activation and inhibiting transcription of interleukin required for T cell proliferation (64).”
BackgroundSwingle, M. R., & Honkanen, R. E. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180508095242 · Cited by 39
Unleashing cell-penetrating peptide applications for immunotherapy
Koo, J., Kim, G., Nam, K.-H., & Choi, J. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.03.010 · Cited by 45
Haleckova, A., Benek, O., Zemanová, L., Doležal, R., & Musílek, K. (2022) · Medicinal Research Reviews · doi:10.1002/med.21892 · Cited by 45
“immunosuppressive function is mediated via CypA binding and the consequent inhibition of calcineurin, which occur independently of CypD inhibition.(81,82) Unfortunately, clinical trials of CsA did not reproduce the promising effects on mPT‐related diseases previously observed in animal studies.”
BackgroundMeira, C. S., Filho, J. M. D. S., Sousa, C. C., Anjos, P. S., Cerqueira, J. V., Neto, H. A. D., da Silveira, R. G., Mannochio-Russo, H., Wolfender, J., Queiroz, E. F., et al. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.02.047 · Cited by 37
Gathogo, E., Harber, M. A., Bhagani, S. R., Levy, J. B., Jones, R., Hilton, R. M., Davies, G., & Post, F. A. (2015) · Transplantation · doi:10.1097/tp.0000000000000879 · Cited by 38
“50 Hepatitis C coinfection, n (%) 4 (5) 3 (10) 1 (2) 0.”
Wakamatsu, A., Fukusumi, Y., Hasegawa, E., Tomita, M., Watanabe, T., Narita, I., & Kawachi, H. (2016) · Physiological Reports · doi:10.14814/phy2.12679 · Cited by 36
“It is understood that CNIs decreased the production of cytokines such as IL-2 and IL-4 (O’Keefe et al. 1992; Bram et al. 1993; Azzi et al. 2013), by inhibiting the activation of a nuclear factor of an activated T cell (NFAT), a substrate of CN in T cells.”
BackgroundLi, Y., Palmisano, M., Sun, D., & Zhou, S. Y. (2020) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s255789 · Cited by 36
Rafael‐Vidal, C., Altabás‐González, I., Pérez, N., Mouriño, C., Pego‐Reigosa, J. M., & García, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031263 · Cited by 35
Treg Therapy for the Induction of Immune Tolerance in Transplantation—Not Lost in Translation?
Pilat, N., Steiner, R., & Sprent, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021752 · Cited by 33
“Like Cyclosporin A and Tacrolimus, CNIs act by inhibiting the translocation of NFAT into the nucleus, thereby blocking Teff function and synthesis of IL-2, the latter being crucial for survival and maintenance of Tregs, though less important for Teff [39,40].”
BackgroundHBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review
Gentile, G., & Antonelli, G. (2019) · Viruses · doi:10.3390/v11111049 · Cited by 38
“For example, cyclosporin, an immunophilin inhibitor, suppresses T-lymphocyte activity [55] and the use of high-dose steroids suppresses cell-mediated immunity by inhibiting the production”
BackgroundTargeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma
Bucher, P., Erdmann, T., Grondona, P., Xu, W., Schmitt, A., Schürch, C., Zapukhlyak, M., Schönfeld, C., Serfling, E., Kramer, D., et al. (2019) · Blood · doi:10.1182/blood.2019001866 · Cited by 32
Poli, V., Gioia, M. D., Sola-Visner, M. C., Granucci, F., Frelinger, A. L., Michelson, A. D., & Zanoni, I. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.002 · Cited by 32
Structure-guided approaches to targeting stress responses in human fungal pathogens
LeBlanc, E. V., Polvi, E. J., Veri, A. O., Privé, G. G., & Cowen, L. E. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.013731 · Cited by 35
“In humans, calcineurin plays a key role inmany cellular signaling processes, including T-cell activation (60), and is the target of immunosuppressive drugs used in the clinic (61).”
BackgroundAlvarez, J., Kwun, H. J., Artusi, S., Chang, Y., & Moore, P. S. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa071 · Cited by 31
“Both mechanistic target of rapamycin (mTOR) and calcineurin inhibitors are widely used as immunosuppressants following organ transplantation [13, 14].”
BackgroundWang, H., Ji, Z., Feng, Y., Yan, T., Cao, Y., Lu, H., & Jiang, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1101553 · Cited by 30
“Tacrolimus binds to an FK506-binding protein (FKBP12) and inhibits calcineurin, and targets of rapamycin complex 1 (TORC1), which is important for ribosome biosynthesis (Azzi et al., 2013; Kasahara, 2021).”
BackgroundMicrobe-associated immunomodulatory metabolites: Influence on T cell fate and function
Castro, C. N., Freitag, J., Berod, L., Lochner, M., & Sparwasser, T. D. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.07.025 · Cited by 30
Hoy, M. J., Park, E., Lee, H., Lim, W. Y., Cole, D., DeBouver, N. D., Bobay, B. G., Pierce, P. G., Fox, D., Ciofani, M., et al. (2022) · mBio · doi:10.1128/mbio.01049-22 · Cited by 33
“makes it unsuitable to treat patients with fungal infections (24).”
Nguyen, K., Kempfle, J. S., Jung, D. H., & McKenna, C. E. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1252751 · Cited by 30
“Thus, cyclosporine A and other calcineurin inhibitors (CNIs) are mainly used to address transplant rejections and to treat autoimmune diseases [112].”
BackgroundYasuda, H., Fukusumi, Y., Ivanov, V., Zhang, Y., & Kawachi, H. (2021) · The FASEB Journal · doi:10.1096/fj.202101052r · Cited by 30
Atherosclerosis in Systemic Lupus Erythematosus
Tobin, R. S., Patel, N. H., Tobb, K., Weber, B., Mehta, P. K., & Isiadinso, I. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01149-4 · Cited by 36
Ericson, J. E., Zimmerman, K. O., González, D., Melloni, C., Guptill, J. T., Hill, K. D., Wu, H., & Cohen‐Wolkowiez, M. (2016) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000364 · Cited by 28
Glicklich, D. G., Lamba, R., & Pawar, R. (2016) · Cardiology in Review · doi:10.1097/crd.0000000000000126 · Cited by 31
Erro, R., Bacchin, R. A., Magrinelli, F., Tomei, P., Geroin, C., Squintani, G. M., Lupo, A., Zaza, G., & Tinazzi, M. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8904-x · Cited by 28
Mané-Damas, M., Molenaar, P. C., Ulrichts, P., Marcuse, F. D., Baets, M. H. D., Martínez‐Martínez, P., & Losen, M. H. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103104 · Cited by 31
Leonczak, P., Gao, L., Ramadori, A. T., Lescrinier, E., Rozenski, J., Jonghe, S. D., & Herdewijn, P. A. (2014) · ChemMedChem · doi:10.1002/cmdc.201402234 · Cited by 27
Taber, D. J., Hunt, K. J., Gebregziabher, M., Srinivas, T. R., Chavin, K. D., Baliga, P. K., & Egede, L. E. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04880516 · Cited by 28
“To address the latter issue, transplant programs have implemented and tested protocols that seek to minimize or eliminate the long-term use of immunosuppressant medication with considerable toxicities (5,6).”
BackgroundSubcellular Distribution of HDAC1 in Neurotoxic Conditions Is Dependent on Serine Phosphorylation
Zhu, Y., Vidaurre, Ó. G., Adula, K. P., Kezunovic, N., Wentling, M., Huntley, G. W., & Casaccia, P. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.3000-16.2017 · Cited by 31
“To test this hypothesis, we pretreated primary neurons with two independent calcineurinspecific pharmacological inhibitors, FK506 and cyclosporin A (CyA) (Liu et al., 1991; Azzi et al., 2013), and then exposed them to treatment with glutamate/TNF .”
MethodCyclosporin a induces renal episodic hypoxia
Fähling, M., Mathia, S., Scheidl, J., Abramovitch, R., Milman, Z., Paliege, A., Peters, H., Persson, P. B., Heyman, S. N., & Rosenberger, C. (2016) · Acta Physiologica · doi:10.1111/apha.12811 · Cited by 26
“…early 1970s, the calcineurin inhibitor immunosuppressant cyclosporin A (CsA) soon gained clinical application, and became a standard of care in organ transplantation, as well as an important treatment option in a variety of autoimmune diseases (for reviews, see Azzi et al. 2013, Issa et al. 2013).”
BackgroundTrombino, S., Servidio, C., Laganà, A. S., Conforti, F., Marrelli, M., & Cassano, R. (2020) · Molecules · doi:10.3390/molecules25153535 · Cited by 26
“Its mechanism of action is attributable to the inhibition of calcineurin that consequently leads to the inactivation of T cells and downregulation of the expression of proinflammatory mediators, particularly IL-2 and IL-4 [8].”
BackgroundNeurologic Toxicities Associated with Tumor Necrosis Factor Inhibitors and Calcineurin Inhibitors
Coe, C. L., Horst, S., & Izzy, M. J. (2020) · Neurologic Clinics · doi:10.1016/j.ncl.2020.07.009 · Cited by 25
Matsumoto, Y., Yoshikawa, A., Nagamachi, T., Sugiyama, Y., Yamada, T., & Sugita, T. (2022) · Scientific Reports · doi:10.1038/s41598-022-20507-x · Cited by 26
Lee, S. W., Oh, Y. M., Victor, M. B., Yang, Y., Chen, S., Strunilin, I., Dahiya, S. M., Dolle, R. E., Pak, S. C., Silverman, G. A., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00538-3 · Cited by 30
Qu, D., Tian, X., Ding, L., Li, Y., & Zhou, W. (2021) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-021-00728-x · Cited by 26
Cyclosporine A lipid nanoparticles for oral administration: Pharmacodynamics and safety evaluation
Guada, M., Lana, H., Gil, A. G., Dios-Viéitez, M. D. C., & Blanco‐Prieto, M. J. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.01.011 · Cited by 24
Zemel, B. M., Muqeem, T., Brown, E. V., Goulão, M., Urban, M. W., Tymanskyj, S. R., Lepore, A. C., & Covarrubias, M. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.0434-17.2017 · Cited by 24
“The immunosuppressants tacrolimus (FK506) and cyclosporin A (CsA) are CaN inhibitors responsible for CaN inhibitor-induced pain syndrome (CIPS) in subsets of transplant patients (Grotz et al., 2001; Fujii et al., 2006; Noda et al., 2008; Prommer, 2012; Azzi et al., 2013).”
BackgroundPapasavvas, I., & Herbort, C. P. (2022) · Medicina · doi:10.3390/medicina58020165 · Cited by 24
“Tacrolimus has the same mechanism of action as CsA, but has a better toxicity profile with at least similar if not better efficacy [26].”
BackgroundOverview of Venous Thrombosis in Inflammatory Bowel Disease
Pürnak, T., & Yüksel, O. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000274 · Cited by 28
“Cyclosporine and tacrolimus mainly inhibit IL-2 and T-helper function and are used in the treatment of refractory colitis to prevent surgery.(76) It is thought that cyclosporine may cause thrombogenesis and platelet aggregation along with endothelial damage in the body.”
BackgroundVenuto, R. C., Meaney, C. J., Chang, S. S., Leca, N., Consiglio, J. D., Wilding, G. E., Brazeau, D. A., Gundroo, A. A., Nainani, N., Morse, S. E., et al. (2015) · Medicine · doi:10.1097/md.0000000000001315 · Cited by 24
Calcineurin-dependent contributions to fitness in the opportunistic pathogen Candida glabrata
Pavesic, M. W., Gale, A. N., Nickels, T. J., Harrington, A. A., Bussey, M., & Cunningham, K. W. (2024) · mSphere · doi:10.1128/msphere.00554-23 · Cited by 22
“immunosuppressants, as the NFAT transcription factors in human T‐cells critically depend on 42 calcineurin signaling for triggering normal immune responses (2).”
BackgroundNew Approaches to the Diagnosis of Rejection and Prediction of Tolerance in Liver Transplantation
Taner, T., Bruner, J., Emamaullee, J. A., Bonaccorsi‐Riani, E., & Zarrinpar, A. (2022) · Transplantation · doi:10.1097/tp.0000000000004160 · Cited by 26
“One of the key factors is the introduction of calcineurin inhibitor-based immunosuppression (IS) in the 1980s, which has become the standard of care for most transplant recipients.(2) However, acute rejection occurs in 15% to 35% of LT recipients in the first 2 y after transplant.”
BackgroundEffects of embryonic cyclosporine exposures on brain development and behavior
Clift, D. E., Thorn, R. J., Passarelli, E., Kapoor, M., LoPiccolo, M. K., Richendrfer, H. A., Colwill, R. M., & Créton, R. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.01.006 · Cited by 22
Carreras‐Planella, L., Juega, J., Taco, O., Cañas, L., Franquesa, M., Lauzurica, R., & Borràs, F. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207569 · Cited by 22
“About 94% of renal-transplanted patients receive a CNI-based immunosuppressive regime [7], yet it is well-known that CNI treatment can produce nephrotoxicity, commonly referred to as CNI toxicity (CNIT) [8].”
BackgroundCyclophilin D, a target for counteracting skeletal muscle dysfunction in mitochondrial myopathy
Gineste, C., Hernandez, A., Ivarsson, N., Cheng, A. J., Naess, K., Wibom, R., Lesko, N., Bruhn, H., Wedell, A., Freyer, C., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv361 · Cited by 21
Itch in Atopic Dermatitis Management
Kamata, Y., Tominaga, M., & Takamori, K. (2016) · Current problems in dermatology · doi:10.1159/000446048 · Cited by 21
Oberhofer, M., Wackerlig, J., Zehl, M., Büyük, H., Cao, J. J., Roller, A., Urban, E., & Zotchev, S. B. (2021) · ACS Omega · doi:10.1021/acsomega.0c05472 · Cited by 22
The mitochondrial sodium/calcium exchanger NCLX (Slc8b1) in B lymphocytes
Emrich, S. M., Yoast, R. E., Fike, A. J., Bricker, K. N., Xin, P., Zhang, X., Rahman, Z. S. M., & Trebak, M. (2022) · Cell Calcium · doi:10.1016/j.ceca.2022.102667 · Cited by 26
The TWEAK/Fn14 pathway is required for calcineurin inhibitor toxicity of the kidneys
Claus, M., Herro, R., Wolf, D., Buscher, K., Rudloff, S., Huynh‐Do, U., Burkly, L. C., Croft, M., & Sidler, D. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14632 · Cited by 21
Complications of Treatments for Pediatric Rheumatic Diseases
Higgins, G. C. (2018) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2018.04.008 · Cited by 22
Inositol Requiring Enzyme (IRE), a multiplayer in sensing endoplasmic reticulum stress
Zhou, Z., Wang, Q., & Michalak, M. (2021) · Animal Cells and Systems · doi:10.1080/19768354.2021.2020901 · Cited by 24
“Cyclosporine is an inhibitor of a Ca2+-dependent phosphatase, calcineurin, and it is widely used as an immunosuppressant drug (Azzi et al. 2013).”
Background
Metadata
- Authors
- Azzi, J. R., Sayegh, M. H., & Mallat, S. G.
- Affiliations
- Brigham and Women's Hospital (US)
- American University of Beirut (LB)
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-12
- Volume
- 191
- Issue
- 12
- Pages
- 5785-5791
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1592567691
- Cited by
- 337
- References
- 90
- Citations by year
- 2026: 17 · 2025: 31 · 2024: 26 · 2023: 32 · 2022: 44 · 2021: 38 · 2020: 27 · 2019: 27 · 2018: 25 · 2017: 17 · 2016: 25 · 2015: 14 · 2014: 12
- FWCI
- 12.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- calcineurin inhibitors, cyclosporine, tacrolimus, organ transplantation, immunosuppression, nephrotoxicity, drug toxicity reduction, autoimmune disease therapy, mechanism of action
- MeSH terms
- Animals, Autoimmune Diseases, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Drug Evaluation, Preclinical, Drug Therapy, Combination, Forecasting, Graft Rejection, Humans, Immunosuppressive Agents, Kidney Diseases, Lymphocyte Activation, T-Lymphocytes, Meta-Analysis as Topic, Multicenter Studies as Topic, Kidney Transplantation, Randomized Controlled Trials as Topic, Tacrolimus, Cyclosporine, Calcineurin, History, 20th Century, History, 21st Century, Calcineurin Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.